Extrinsic factors can adversely affect immune responses, producing states of secondary
immunodeficiency and consequent increased risk of infections. These immunodeficiencies …

Renal transplant recipients have increased mortality rates when compared with the general
population. The new immunosuppressive drugs have improved short-term patient survival …

Background In previous analyses of BENEFIT, a phase 3 study, belatacept-based
immunosuppression, as compared with cyclosporine-based immunosuppression, was …

The clinical profile of belatacept in kidney transplant recipients was evaluated to determine if
earlier results in the BENEFIT study were sustained at 3 years. BENEFIT is a randomized 3 …

This review aims to provide an update of the literature on the pharmacology and toxicology
of mycophenolate in solid organ transplant recipients. Mycophenolate is now the …

Background. Cardiovascular disease, the most common cause of death with a functioning
graft among kidney transplant recipients, can be exacerbated by immunosuppressive drugs …

In this Phase 2b study, 331 low-to-moderate risk de novo kidney transplant patients
(approximately 60% deceased donors) were randomized to a more intensive (MI) or less …

Human leukocyte antigen (HLA) mismatches have been shown to adversely affect renal
allograft outcomes and remain an important component of the allocation of deceased donor …

Induction therapy with antilymphocyte biological agents is widely used after kidney
transplantation, most commonly T lymphocyte-depleting rabbit-derived antithymocyte …

BACKGROUND: Immunosuppression is associated with a number of adverse outcomes, but
typically it is the physician, not the patient, who decides on the drug regimen. The …